Serum glycans as risk markers for non-small cell lung cancer

Cancer Prevention Research

Volumn 9, Issue 4, 2016, Pages 317-323

  Ruhaak, L Renee ^a,b   Stroble, Carol ^a,c   Dai, Jianliang ^b   Barnett, Matt ^d   Taguchi, Ayumu ^b   Goodman, Gary E ^d   Miyamoto, Suzanne ^c   Gandara, David ^c   Feng, Ziding ^b   Lebrilla, Carlito B ^a   Hanash, Samir ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CAROTENE; GLYCAN; RETINOL PALMITATE; POLYSACCHARIDE; PRO-SFTPB PROTEIN, HUMAN; PROTEIN PRECURSOR; SURFACTANT ASSOCIATED PROTEIN; TUMOR MARKER;

ADULT; AGE; ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLYCOBIOLOGY; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MULTICENTER STUDY; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX; SMOKING; VALIDATION STUDY; VITAMIN SUPPLEMENTATION; AGED; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; MIDDLE AGED; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR;

AGED; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MASS SPECTROMETRY; MIDDLE AGED; POLYSACCHARIDES; PREDICTIVE VALUE OF TESTS; PROTEIN PRECURSORS; PULMONARY SURFACTANT-ASSOCIATED PROTEINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS;

EID: 84964034061     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-15-0033     Document Type: Article

References (28)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. National Lung Screening Trial Research T, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al.Reduced lung-cancer mortality with lowdose computed tomographic screening. N Engl J Med 2011;365: 395-409.
3. Sin DD, Tammemagi CM, Lam S, Barnett MJ, Duan X, Tam A, et al.Prosurfactant protein B as a biomarker for lung cancer prediction. J Clin Oncol 2013;31:4536-43.
4. Taguchi A, Hanash S, Rundle A, McKeague IW, Tang D, Darakjy S, et al. Circulating pro-surfactant protein B as a risk biomarker for lung cancer. Cancer Epidemiol Biomarkers Prev 2013;22:1756-61.
5. Wikoff WR, Hanash S, DeFelice B, Miyamoto S, Barnett M, Zhao Y, et al. Diacetylspermine is a novel prediagnostic serum biomarker for non-smallcell lung cancer and has additive performance with pro-surfactant protein B. J Clin Oncol 2015;33:3880-6.
6. Packer NH, von der Lieth CW, Aoki-Kinoshita KF, Lebrilla CB, Paulson JC, Raman R, et al.Frontiers in glycomics: bioinformatics and biomarkers in disease. An NIH white paper prepared from discussions by the focus groups at a workshop on the NIH campus, Bethesda MD (September 11-13, 2006). Proteomics 2008;8:8-20.
7. Ruhaak LR, Miyamoto S, Lebrilla CB. Developments in the identification of glycan biomarkers for the detection of cancer. Mol Cell Proteomics 2013;12:846-55.
8. Kornfeld R, Kornfeld S. Assembly of asparagine-linked oligosaccharides. Annu Rev Biochem 1985;54:631-64.
9. Hoagland LF, Campa MJ, Gottlin EB, Herndon JE, Patz EFJr. Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer. Cancer 2007;110:2260-8.
10. Arnold JN, Saldova R,Galligan MC, Murphy TB, Mimura-Kimura Y, Telford JE, et al.Novel glycan biomarkers for the detection of lung cancer. J Proteome Res 2011;10:1755-64.
11. Vasseur JA, Goetz JA, Alley WRJr, Novotny MV. Smoking and lung cancerinduced changes in N-Glycosylation of blood serum proteins. Glycobiology 2012;22:1684-708.
12. Ruhaak LR, Nguyen UT, Stroble C, Taylor SL, Taguchi A, Hanash SM, et al. Enrichment strategies in glycomics based lung cancer biomarker development. Proteomics Clin Appl 2013;7:664-76.
13. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 2008;100:1432-8.
14. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-61.
15. Goodman GE, Thornquist MD, Balmes J, Cullen MR, Meyskens FLJr, Omenn GS, et al.The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year followup after stopping beta-carotene and retinol supplements. J Natl Cancer Inst 2004;96:1743-50.
16. Kronewitter SR, An HJ, de Leoz ML, Lebrilla CB, Miyamoto S, Leiserowitz GS. The development of retrosynthetic glycan libraries to profile and classify the human serum N-linked glycome. Proteomics 2009;9:2986-94.
17. Ruhaak LR, Taylor SL, Miyamoto S, Kelly K, Leiserowitz GS, Gandara D, et al.Chip-based nLC-TOF-MS is a highly stable technology for large-scale high-throughput analyses. Anal Bioanal Chem 2013;405:4953-8.
18. Dodd LE, Pepe MS. Partial AUC estimation and regression. Biometrics 2003;59:614-23.
19. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
20. Ruhaak LR, Barkauskas DA, Torres J, Cooke CL, Wu LD, Stroble C, et al.The serum immunoglobulin G glycosylation signature of gastric cancer. EuPA Open Proteom 2015;6:1-9.
21. Schwedler C, Kaup M, Petzold D, Hoppe B, Braicu EI, Sehouli J, et al.Sialic acid methylation refines capillary electrophoresis laser-induced fluorescence analyses of immunoglobulinG N-glycans of ovarian cancer patients. Electrophoresis 2014;35:1025-31.
22. Kodar K, Stadlmann J, Klaamas K, Sergeyev B, Kurtenkov O. Immunoglobulin G Fc N-glycan profiling in patients with gastric cancer by LC-ESIMS: relation to tumor progression and survival. Glycoconj J 2012;29: 57-66.
23. Qian Y, Wang Y, Zhang X, Zhou L, Zhang Z, Xu J, et al.Quantitative analysis of serum IgG galactosylation assists differential diagnosis of ovarian cancer. J Proteome Res 2013;12:4046-55.
24. Selman MHJ, Niks EH, Titulaer MJ, Verschuuren JJGM, Wuhrer M, Deelder AM. IgG Fc N-glycosylation changes in lambed-eaton myasthenic syndrome and myasthenia gravis. J Proteome Res 2011;10:143-52.
25. Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 1985;316: 452-7.
26. Wuhrer M, Stavenhagen K, Koeleman CA, Selman MH, Harper L, Jacobs BC, et al.Skewed Fc glycosylation profiles of anti-proteinase 3 immunoglobulin G1 autoantibodies from granulomatosis with polyangiitis patients show low levels of bisection, galactosylation, and sialylation. J Proteome Res 2015;14:1657-65.
27. Saldova R, Royle L, Radcliffe CM, Abd Hamid UM, Evans R, Arnold JN, et al. Ovarian cancer is associated with changes in glycosylation in both acutephase proteins and IgG. Glycobiology 2007;17:1344-56.
28. Moore JS, Wu X, Kulhavy R, Tomana M, Novak J, Moldoveanu Z, et al. Increased levels of galactose-deficient IgG in sera of HIV-1-infected individuals. AIDS 2005;19:381-9.